A Descriptive Observational Study of Real-Time TDM-Guided Aggressive PK/PD Target Attainment and Microbiological/Clinical Outcome in Patients with Stenotrophomonas maltophilia Bloodstream Infections and/or Pneumonia Treated with Continuous Infusion Cefiderocol.
4 affiliations
- 1Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy.
- 2Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- 3Infectious Disease Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy.
- 4Operative Unit of Microbiology, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Abstract
Objectives
To assess whether attaining an aggressive pharmacokinetic/pharmacodynamic (PK/PD) target with continuous infusion (CI) cefiderocol could be an effective strategy for managing documented bloodstream infections (BSIs) and pneumonia caused by Stenotrophomonas maltophilia, and to identify independent predictors of microbiological and clinical failure.Methods
Patients receiving CI cefiderocol according to a real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program for managing documented BSIs and/or pneumonia caused by Stenotrophomonas maltophilia were retrospectively included. Free fractions of plasma cefiderocol steady-state concentrations (fCss) were calculated according to a protein binding of 58%, and aggressive PK/PD target was defined as the attainment of a fCss/MIC ratio > 4. Exploratory multivariate analysis was implemented for assessing potential independent predictors of microbiological and clinical failure.Results
Overall, 25 patients (14 BSIs, 10 pneumonia, and one bacteremic pneumonia) were included. Early and overall aggressive cefiderocol PK/PD target was attained in 100.0% of cases. Microbiological eradication rate was 75.0% (15/20) among patients having available follow-up cultures, whereas clinical cure rate was 60.0% (15/25). No case of resistance occurrence to cefiderocol emerged. Bacteremia emerged as the only potential predictor of reduced risk of microbiological failure (odds ratio [OR] 0.04; 95%CI 0.01-0.54; p = 0.016), whereas mechanical ventilation was potentially associated with higher risk of clinical failure (OR 15.17; 95%CI 2.03-111.35; p = 0.008). No significant differences between cefiderocol mono- or combination therapy in terms of microbiological and/clinical outcome were found.Conclusions
Our findings could suggest that CI cefiderocol could be a feasible way for attaining aggressive PK/PD target. This approach could represent a valuable strategy for favoring the microbiological eradication and/or clinical cure of documented Stenotrophomonas maltophilia infections with cefiderocol monotherapy in critical immunocompromised patients. Prospective comparative studies would be warranted for confirming our hypothesis.
Related
- Antibiotic resistance and prevalence of Stenotrophomonas maltophilia isolated from clinical samples.
- The role of the polysaccharide capsule as a novel virulence-associated trait of Stenotrophomonas maltophilia complex bacteria
- Whole-genome characterization of clinical Stenotrophomonas maltophilia in Lebanon: sequence types, resistome, and T6SS diversity
- Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
- Empirical antibacterial use, escalation, microbiological profile, and outcomes in febrile neutropenia: An ambispective observational study
BibTeX
@article{gatti2026descriptive,
title = {{A Descriptive Observational Study of Real-Time TDM-Guided Aggressive PK/PD Target Attainment and Microbiological/Clinical Outcome in Patients with Stenotrophomonas maltophilia Bloodstream Infections and/or Pneumonia Treated with Continuous Infusion Cefiderocol.}},
author = {Milo Gatti and Matteo Rinaldi and Simone Ambretti and Maddalena Giannella and Pierluigi Viale and Federico Pea},
journal = {Antibiotics (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/antibiotics15100990},
url = {https://europepmc.org/article/MED/42938731},
note = {CC BY},
}
RIS
TY - JOUR
TI - A Descriptive Observational Study of Real-Time TDM-Guided Aggressive PK/PD Target Attainment and Microbiological/Clinical Outcome in Patients with Stenotrophomonas maltophilia Bloodstream Infections and/or Pneumonia Treated with Continuous Infusion Cefiderocol.
AU - Milo Gatti
AU - Matteo Rinaldi
AU - Simone Ambretti
AU - Maddalena Giannella
AU - Pierluigi Viale
AU - Federico Pea
PY - 2026
DA - 2026/10/07
JO - Antibiotics (Basel, Switzerland)
DO - 10.3390/antibiotics15100990
UR - https://europepmc.org/article/MED/42938731
AB - Objectives To assess whether attaining an aggressive pharmacokinetic/pharmacodynamic (PK/PD) target with continuous infusion (CI) cefiderocol could be an effective strategy for managing documented bloodstream infections (BSIs) and pneumonia caused by Stenotrophomonas maltophilia, and to identify independent predictors of microbiological and clinical failure.Methods Patients receiving CI cefiderocol according to a real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program for managing documented BSIs and/or pneumonia caused by Stenotrophomonas maltophilia were retrospectively included. Free fractions of plasma cefiderocol steady-state concentrations (fCss) were calculated according to a protein binding of 58%, and aggressive PK/PD target was defined as the attainment of a fCss/MIC ratio > 4. Exploratory multivariate analysis was implemented for assessing potential independent predictors of microbiological and clinical failure.Results Overall, 25 patients (14 BSIs, 10 pneumonia, and one bacteremic pneumonia) were included. Early and overall aggressive cefiderocol PK/PD target was attained in 100.0% of cases. Microbiological eradication rate was 75.0% (15/20) among patients having available follow-up cultures, whereas clinical cure rate was 60.0% (15/25). No case of resistance occurrence to cefiderocol emerged. Bacteremia emerged as the only potential predictor of reduced risk of microbiological failure (odds ratio [OR] 0.04; 95%CI 0.01-0.54; p = 0.016), whereas mechanical ventilation was potentially associated with higher risk of clinical failure (OR 15.17; 95%CI 2.03-111.35; p = 0.008). No significant differences between cefiderocol mono- or combination therapy in terms of microbiological and/clinical outcome were found.Conclusions Our findings could suggest that CI cefiderocol could be a feasible way for attaining aggressive PK/PD target. This approach could represent a valuable strategy for favoring the microbiological eradication and/or clinical cure of documented Stenotrophomonas maltophilia infections with cefiderocol monotherapy in critical immunocompromised patients. Prospective comparative studies would be warranted for confirming our hypothesis.
SN - 2079-6382
ER -